论文部分内容阅读
腺病毒(adenovirus)作为基因治疗和重组疫苗研究的载体已经有广泛的应用,但抗载体免疫限制了其应用。近年来,采用“衣壳嵌合”方法制备的重组腺病毒载体已成为艾滋病、疟疾等疫苗研究的热点,该策略在不影响病毒的感染性及稳定性的前提下,在腺病毒载体衣壳中嵌入外源性抗原从而获得具有新的抗原特性的重组腺病毒粒子。六邻体、五邻体基座、纤维蛋白、多肽Ⅸ、多肽Ⅲa等多种衣壳蛋白的适当位点可以嵌入外源抗原并诱导特异性的免疫应答。本文主要综述了腺病毒“衣壳嵌合”策略应用于疫苗研究中的最新进展。
Adenovirus has been widely used as a vector for gene therapy and recombinant vaccine research, but anti-vector immunity has limited its application. In recent years, the use of “capsid chimeric ” method of preparation of recombinant adenovirus vector has become AIDS, malaria and other vaccine research hot spots, this strategy does not affect the virus infectivity and stability of the premise, in the adenovirus vector Encapsulated with exogenous antigens to obtain recombinant adenovirus particles with novel antigenic properties. Suitable sites for many capsid proteins, such as hexon, penton base, fibrin, polypeptide IX and polypeptide IIIa, can be embedded with foreign antigens and induce specific immune responses. This review summarizes the recent advances in the application of adenovirus “chimeric ” strategy in vaccine research.